<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03571633</url>
  </required_header>
  <id_info>
    <org_study_id>ET17-057</org_study_id>
    <secondary_id>2017-002069-22</secondary_id>
    <nct_id>NCT03571633</nct_id>
  </id_info>
  <brief_title>Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer</brief_title>
  <acronym>BREASTIMMU02</acronym>
  <official_title>A Multicenter, Randomized, Open-label, Phase II Trial Aiming to Evaluate the Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2 Positive Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      First preclinical data suggest that pegfilgrastim could constitute a potent adjuvant for
      immunotherapy with mAb possessing ADCC/ADCP properties as trastuzumab. Combined treatment of
      pegfilgrastim and trastuzumab should translate into an increased rate of pathological
      clinical response. Therefore the investigators' proposal is to evaluate the clinical and
      biological impact of pegfilgrastim in combination with trastuzumab + paclitaxel in
      HER2-positive early stage breast cancer patients. Breastimmune02 is a multicenter,
      randomized, open-label, Phase II trial. Operable HER2+ breast cancer patients previously
      treated with 4 cycles of standard adriamycine/cyclophosphamide (AC) chemotherapy will be
      randomized (1:1) to receive in the neoadjuvant setting:Arm A: weekly paclitaxel + trastuzumab
      (every 3 weeks, Q3W) + pegfilgrastim (Q3W) versus Arm B: weekly paclitaxel + trastuzumab
      (Q3W).Stratification criteria will be: cN0 versus cN1.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of the neoadjuvant treatment period is planned to be 12 weeks (4 cycles of 3
      weeks), except in case of Inacceptable toxicity, or Patient decision, or Withdrawal of
      consent, or Clinical/radiological signs of disease progression.This neoadjuvant treatment
      period will be ended with a short term safety visit (STSVNeo) to be scheduled 28 days after
      the last dose of study treatments (considering the latest study treatments administered).
      Following the STSVNeo, patients will undergo surgery as per usual practice and pathological
      response will be centrally assessed by a referent pathologist blinded for the treatment
      arms.Following surgery, all patients will be treated in the adjuvant setting with trastuzumab
      administered every 3 weeks for up to 12 months in both arms with clinical assessments every 3
      months (cf. Réseau régional de Cancérologie,
      http://espacecancer.sante-ra.fr/Pages/Accueil.aspx). In case of RH+ disease, endocrine
      therapy may be initiated as per standard treatment guidelines.This adjuvant treatment period
      is planned for a maximum of 12 months; except in case of Inacceptable toxicity, or Patient
      decision, or Withdrawal of consent, or Clinical/radiological signs of disease progression.
      All randomized and treated patients will be followed-up for relapse and survival for at least
      15 months post-randomization (i.e. 1 year post-surgery).

      A total of 90 patients will be randomized in the study. (45 per arm). All the data concerning
      the patients will be recorded in the electronic case report form (eCRF) throughout the study
      serious adverse event (SAE) reporting will be also paper-based by e-mail and/or Fax. The
      sponsor will perform the study monitoring and will help the investigators to conduct the
      study in compliance with the clinical trial protocol, Good Clinical Practices (GCP) and local
      law requirements
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 6, 2018</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response rate (pCR)</measure>
    <time_frame>16 weeks after start of treatment</time_frame>
    <description>Defined as ypT0 ypN0 or ypT0/is ypN0 after 12 weeks of treatment by trastuzumab + paclitaxel ± pegfilgrastim with ypT0/Tis ypN0 defined as absence of invasive cancer in the breast and axillary nodes in all surgically excised specimens.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Free survival</measure>
    <time_frame>At least 15 months following randomisation</time_frame>
    <description>From the date of randomisation until the date of event defined as the first documented relapse after surgery or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to relapse</measure>
    <time_frame>At least 15 months following randomisation</time_frame>
    <description>From the time of treatment start until the first documented relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>At least 15 months following randomisation</time_frame>
    <description>From the date of randomisation to the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events reporting</measure>
    <time_frame>At least 15 months following randomisation</time_frame>
    <description>Based mainly on the frequency of AE graded according to the common toxicity criteria grading system (CTCAE-V4.03).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Trastuzumab ADCC activity</measure>
    <time_frame>At Baseline, at Day 1 of Cycle 2 (each cycle is a 21-day cycle) and at surgery</time_frame>
    <description>Analysis of the levels of the ADCC tumor samples</description>
  </other_outcome>
  <other_outcome>
    <measure>HER2 signaling</measure>
    <time_frame>At Baseline, at Day 1 of Cycle 2 (each cycle is a 21-day cycle) and at surgery</time_frame>
    <description>Evaluation of the levels of phosphorylated components of PI3K/mTOR and Ras/Raf /MAPK signaling (IHC or IF)</description>
  </other_outcome>
  <other_outcome>
    <measure>Immune effector cells activity</measure>
    <time_frame>At Baseline, at Day 1 of Cycle 2 (each cycle is a 21-day cycle) and at surgery</time_frame>
    <description>Analysis of activity of immune effector cells (frequency, function, activation status and ADCC)</description>
  </other_outcome>
  <other_outcome>
    <measure>TGFbeta levels</measure>
    <time_frame>At Baseline</time_frame>
    <description>Levels of TGFβ (bioactive and non-bioactive) in serum, plasma and platelets</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>HER2-positive Breast Cancer</condition>
  <condition>Operable Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Paclitaxel+Trastuzumab+Pegfilgrastim</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NEOADJUVANT TREATMENT PERIOD (up to 12 weeks) :Paclitaxel (80 mg/m2, weekly (D1, D8, D15), IV) + Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, IV OR 600mg, Q3W SC) + Pegfilgrastim (6 mg, Q3W, subcutaneously, the day after the trastuzumab + paclitaxel infusion (i.e. Day 2 of each cycle)).
ADJUVANT TREATMENT PERIOD (up to 12 months) : Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, (IV) OR 600mg, Q3W SC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel+Trastuzumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NEOADJUVANT TREATMENT PERIOD (up to 12 weeks) :Paclitaxel (80 mg/m2, weekly (D1, D8, D15), IV) + Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, IV OR 600mg, Q3W SC).
ADJUVANT TREATMENT PERIOD (up to 12 months) : Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, (IV) OR 600mg, Q3W SC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab + Paclitaxel</intervention_name>
    <description>During neoadjuvant period, weekly paclitaxel + trastuzumab (every 3 weeks, Q3W) During adjuvant period, weekly trastuzumab (every 3 weeks, Q3W)</description>
    <arm_group_label>Paclitaxel+Trastuzumab</arm_group_label>
    <arm_group_label>Paclitaxel+Trastuzumab+Pegfilgrastim</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegfilgrastim</intervention_name>
    <description>During neoadjuvant period, weekly pegfilgrastim (every 3 weeks, Q3W)</description>
    <arm_group_label>Paclitaxel+Trastuzumab+Pegfilgrastim</arm_group_label>
    <other_name>Neulasta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients aged ≥ 18 years at time of inform consent signature.

          -  Histologically proven HER2 positive breast cancer defined as 3+ staining intensity by
             immunohistochemistry (IHC) or a 2+ IHC staining intensity and HER2 gene amplification
             by FISH.Note: HER2 status will be determined as per institutional practice.

          -  Operable breast tumor with tumor size and staging: &gt; 20 mm, cN0 or cN1, M0.

          -  No radiological sign of disease progression at time of randomisation.

          -  Patient previously treated by 4 cycles of AC or 3 to 4 cycles of FEC without febrile
             neutropenia and without prior pegfilgrastim treatment.

          -  Availability of a representative formalin-fixed paraffin-embedded (FFPE) tumor
             specimen from initial diagnosis (i.e. an archival paraffin block is preferred; or at
             least 20 unstained slides) with its histological report.

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

          -  Adequate organ function as defined by the following lab tests (to be carried out
             within 7 days prior C1D1):Bone marrow (Absolute neutrophil count ≥ 1.5 x 109/L,
             Platelet count &gt; 100 x 109/L, (without transfusion within 21 days prior to C1D1),
             Hemoglobin value ≥ 9 g/dL), Renal function (Calculated creatinine clearance by MDRD or
             CKD-EPI &gt;50 mL/min/1.73m2 or serum creatinine &lt; 1.5ULN), Liver function (Alanine
             aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3ULN, Total serum
             bilirubin ≤ 1.5 ULN (except for patients with Gilbert disease for whom a total serum
             bilirubin ≤3 ULN is acceptable), Coagulation (INR and aPTT≤ 1.5 ULN)

          -  Adequate cardiac function with Mean resting corrected QT interval (QTc), calculated
             using Fridericia's formula, ≤470ms obtained from 3 electrocardiograms (ECGs) and
             Systolic blood pressure &lt;160mmHg and Diastolic blood pressure &lt;100mmHg (hypertension
             controlled by standard medical treatment is allowed)

          -  Women of childbearing potential (entering the study after a confirmed menstrual period
             and who have a negative pregnancy test within 7 days before C1D1) must agree to use
             two methods of medically acceptable forms of contraception from the date of negative
             pregnancy test to 3 months after the last study drug intake

          -  Patients should be able and willing to comply with study visits and procedures as per
             protocol

          -  Patients should understand, sign, and date the written voluntary informed consent form
             at the screening visit prior to any protocol-specific procedures performed.

          -  Patients must be covered by a medical insurance.

        Exclusion Criteria:

          -  Patients with inflammatory breast cancer.

          -  Previous exposure to pegfilgrastim or trastuzumab. Note: the use of filgrastim (non
             pegylated form only) is authorized prior to the randomisation.

          -  Patients requiring the concomitant use of any forbidden treatment including: Any other
             anti-cancer treatments not listed in the protocol, including chemotherapy,
             radiotherapy, immunotherapy, targeted therapy or biologic therapy for cancer
             treatment, Any investigational treatment.

          -  Any contra-indication to trastuzumab, paclitaxel, and pegfilgrastim respective SPCs
             including:Hypersensitivity to trastuzumab, murine proteins, or to any of the
             excipients listed in trastuzumab SPC, Severe dyspnea at rest due to complications of
             advanced malignancy or requiring supplementary oxygen therapy, Hypersensitivity to
             pegfilgrastim or filgrastim, or to any of the excipients listed in SPC, Hereditary
             problems of fructose intolerance, Hypersensitivity to paclitaxel or to any excipient,
             particularly macrogolglycerol ricinoleate, Patients with history of or active cardiac
             disease including myocardial infarction (MI), angina pectoris requiring medical
             treatment, congestive heart failure NYHA (New York Heart Association) Class ≥II, other
             cardiomyopathy, cardiac arrhythmia requiring medical treatment, clinically significant
             cardiac valvular disease, and hemodynamic effective pericardial effusion.

          -  Active secondary malignancy unless this malignancy is not expected to interfere with
             the evaluation of study endpoints and is approved by the sponsor. Examples of the
             latter include basal or squamous cell carcinoma of the skin, in-situ carcinoma of the
             cervix. Patients with a completely treated prior malignancy and no evidence of disease
             for ≥ 2 years are eligible.

          -  Pregnant or breast-feeding female patients.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier TREDAN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Leon Berard</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier TREDAN, MD</last_name>
    <phone>04 78 78 28 28</phone>
    <email>olivier.tredan@lyon.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien GRENIER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Julien GRENIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier TREDAN</last_name>
    </contact>
    <investigator>
      <last_name>Olivier TREDAN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCL - Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Prive Jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olfa Derbel Miled</last_name>
    </contact>
    <investigator>
      <last_name>Olfa Derbel Miled, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Annecy Genevois</name>
      <address>
        <city>Pringy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie VALLEE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marie VALLEE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Philippe Jacquin</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Philippe Jacquin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Charcot</name>
      <address>
        <city>Sainte-Foy-lès-Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Carrabin</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas Carrabin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010 Dec 15;127(12):2893-917. doi: 10.1002/ijc.25516.</citation>
    <PMID>21351269</PMID>
  </reference>
  <reference>
    <citation>Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF; American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013 Nov 1;31(31):3997-4013. doi: 10.1200/JCO.2013.50.9984. Epub 2013 Oct 7.</citation>
    <PMID>24101045</PMID>
  </reference>
  <reference>
    <citation>Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF; American Society of Clinical Oncology/College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131(1):18-43. doi: 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2.</citation>
    <PMID>19548375</PMID>
  </reference>
  <reference>
    <citation>Zhou BP, Hung MC. Dysregulation of cellular signaling by HER2/neu in breast cancer. Semin Oncol. 2003 Oct;30(5 Suppl 16):38-48. Review.</citation>
    <PMID>14613025</PMID>
  </reference>
  <reference>
    <citation>Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011 Oct 6;365(14):1273-83. doi: 10.1056/NEJMoa0910383.</citation>
    <PMID>21991949</PMID>
  </reference>
  <reference>
    <citation>Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kühn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, von Minckwitz G. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol. 2010 Apr 20;28(12):2024-31. doi: 10.1200/JCO.2009.23.8451. Epub 2010 Mar 22.</citation>
    <PMID>20308670</PMID>
  </reference>
  <reference>
    <citation>Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P, Baselga J. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010 Jan 30;375(9712):377-84. doi: 10.1016/S0140-6736(09)61964-4.</citation>
    <PMID>20113825</PMID>
  </reference>
  <reference>
    <citation>Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, Moliterni A, Vazquez F, Byakhov MJ, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Magazzù D, Heinzmann D, Steinseifer J, Valagussa P, Baselga J. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol. 2014 May;15(6):640-7. doi: 10.1016/S1470-2045(14)70080-4. Epub 2014 Mar 20. Erratum in: Lancet Oncol. 2018 Dec;19(12):e667.</citation>
    <PMID>24657003</PMID>
  </reference>
  <reference>
    <citation>Kute T, Stehle JR Jr, Ornelles D, Walker N, Delbono O, Vaughn JP. Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cells. Oncoimmunology. 2012 Sep 1;1(6):810-821.</citation>
    <PMID>23162748</PMID>
  </reference>
  <reference>
    <citation>Deauvieau F, Ollion V, Doffin AC, Achard C, Fonteneau JF, Verronese E, Durand I, Ghittoni R, Marvel J, Dezutter-Dambuyant C, Walzer T, Vie H, Perrot I, Goutagny N, Caux C, Valladeau-Guilemond J. Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells. Int J Cancer. 2015 Mar 1;136(5):1085-94. doi: 10.1002/ijc.29087. Epub 2014 Aug 6.</citation>
    <PMID>25046660</PMID>
  </reference>
  <reference>
    <citation>Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, Czuczman MS. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5866-73.</citation>
    <PMID>14676108</PMID>
  </reference>
  <reference>
    <citation>Cornet S, Mathé D, Chettab K, Evesque A, Matera EL, Trédan O, Dumontet C. Pegfilgrastim Enhances the Antitumor Effect of Therapeutic Monoclonal Antibodies. Mol Cancer Ther. 2016 Jun;15(6):1238-47. doi: 10.1158/1535-7163.MCT-15-0759. Epub 2016 Mar 17.</citation>
    <PMID>26988998</PMID>
  </reference>
  <reference>
    <citation>Cartron G, Zhao-Yang L, Baudard M, Kanouni T, Rouillé V, Quittet P, Klein B, Rossi JF. Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. J Clin Oncol. 2008 Jun 1;26(16):2725-31. doi: 10.1200/JCO.2007.13.7729. Epub 2008 Apr 21.</citation>
    <PMID>18427151</PMID>
  </reference>
  <reference>
    <citation>Bossuyt V, Provenzano E, Symmans WF, Boughey JC, Coles C, Curigliano G, Dixon JM, Esserman LJ, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Viale G, Cameron D; Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Ann Oncol. 2015 Jul;26(7):1280-91. doi: 10.1093/annonc/mdv161. Epub 2015 May 27. Review.</citation>
    <PMID>26019189</PMID>
  </reference>
  <reference>
    <citation>Lin Y, Kikuchi S, Obata Y, Yagyu K; Tokyo Research Group on Prevention of Gastric Cancer. Serum levels of transforming growth factor beta1 are significantly correlated with venous invasion in patients with gastric cancer. J Gastroenterol Hepatol. 2006 Feb;21(2):432-7.</citation>
    <PMID>16509870</PMID>
  </reference>
  <reference>
    <citation>Tas F, Yasasever CT, Karabulut S, Tastekin D, Duranyildiz D. Serum transforming growth factor-beta1 levels may have predictive and prognostic roles in patients with gastric cancer. Tumour Biol. 2015 Mar;36(3):2097-103. doi: 10.1007/s13277-014-2817-9. Epub 2014 Nov 13.</citation>
    <PMID>25391430</PMID>
  </reference>
  <reference>
    <citation>Lin Y, Kikuchi S, Tamakoshi A, Obata Y, Yagyu K, Inaba Y, Kurosawa M, Kawamura T, Motohashi Y, Ishibashi T; JACC Study Group. Serum transforming growth factor-beta1 levels and pancreatic cancer risk: a nested case-control study (Japan). Cancer Causes Control. 2006 Oct;17(8):1077-82.</citation>
    <PMID>16933058</PMID>
  </reference>
  <reference>
    <citation>Zhao J, Liang Y, Yin Q, Liu S, Wang Q, Tang Y, Cao C. Clinical and prognostic significance of serum transforming growth factor-beta1 levels in patients with pancreatic ductal adenocarcinoma. Braz J Med Biol Res. 2016 Jul 25;49(8). pii: S0100-879X2016000800705. doi: 10.1590/1414-431X20165485.</citation>
    <PMID>27464025</PMID>
  </reference>
  <reference>
    <citation>Tas F, Karabulut S, Yasasever CT, Duranyildiz D. Serum transforming growth factor-beta 1 (TGF-β1) levels have diagnostic, predictive, and possible prognostic roles in patients with melanoma. Tumour Biol. 2014 Jul;35(7):7233-7. doi: 10.1007/s13277-014-1984-z. Epub 2014 Apr 27.</citation>
    <PMID>24771267</PMID>
  </reference>
  <reference>
    <citation>Xu S, Yang S, Sun G, Huang W, Zhang Y. Transforming growth factor-beta polymorphisms and serum level in the development of osteosarcoma. DNA Cell Biol. 2014 Nov;33(11):802-6. doi: 10.1089/dna.2014.2527. Epub 2014 Aug 6.</citation>
    <PMID>25098449</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 4, 2018</study_first_submitted>
  <study_first_submitted_qc>June 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2018</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pegfilgrastim</keyword>
  <keyword>Trastuzumab/Paclitaxel</keyword>
  <keyword>Antibody-dependent cell-mediated cytotoxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

